ABSTRACT
Epidermal melasma is a common hyperpigmentation disorder that can be challenging to treat. Although current treatment options for melasma are limited, topical skin-lightening preparations have widely been used as alternatives to hydroquinone. In this prospective, single-arm, open-label study, treatment of epidermal melasma with a novel cream formulation containing nicotinamide 4%, arbutin 3%, bisabolol 1%, and retinaldehyde 0.05% was associated with reductions in Melasma Area and Severity Index (MASI) scores as well as total melasma surface area as measured by medical imaging software. Treatment outcomes including tolerance and safety profiles as well as patient satisfaction and product appreciation showed this novel cosmetic compound may be valuable in the treatment of epidermal melasma.
Subject(s)
Dermatologic Agents/administration & dosage , Melanosis/drug therapy , Patient Satisfaction , Administration, Cutaneous , Adolescent , Adult , Arbutin/administration & dosage , Dermatologic Agents/adverse effects , Female , Humans , Image Processing, Computer-Assisted , Melanosis/pathology , Middle Aged , Monocyclic Sesquiterpenes , Niacinamide/administration & dosage , Prospective Studies , Retinaldehyde/administration & dosage , Sesquiterpenes/administration & dosage , Severity of Illness Index , Skin Cream , Software , Treatment Outcome , Young AdultABSTRACT
En este trabajo se presentan los resultados de un estudio clínico terapéutico abierto, en el cual se incluyeron 10 pacientes portadoras de melasma que fueron tratadas con un nuevo preparado depigmentante: el producto fue utilizado en dos concentraciones (2 por ciento y 5 por ciento), asociado con ácido glicólico al 10 por ciento, por un período de 60 días. La respuesta fue muy buena y no se observaron efectos secundarios